Skip to content
ESPT
MARKETS / NYSE / Health care / Medical devices and instruments / CNMD
NYSE · ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS · LARGE CAP

Conmed Corp. CNMD

17 fiscal years on record · USD · FY2025 reported · SEC filings only
$1.4B
▲ 5.2% YoY
$47.1M
▼ 64.5% YoY
$150.9M
▼ 2.0% YoY

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

CONMED is a medical technology company that provides devices and equipment for surgical procedures. The Company's products are used by surgeons and other healthcare professionals in specialties including orthopedics, general surgery, gynecology, thoracic surgery and gastroenterology. As of December 31, 2025, it had approximately 3,900 full-time employees, including approximately 2,400 in operations and the remaining in sales, marketing, research and development and administration. Its headquarters are located in Largo, Florida. Its product lines consist of orthopedic surgery, which accounted for 42% of net sales in 2025, and general surgery, which accounted for 58%. In orthopedic surgery, it designs, manufactures and globally distributes products that enable orthopedic surgeons to surgically address sports medicine injuries in the knee, hip, shoulder and lower extremities. Its general surgery product line offers products in the areas of advanced surgical and advanced endoscopic technologies. CONMED Corporation was incorporated under the laws of the State of New York in 1970 and became a Delaware corporation in May 2020.

Written from the business description in CONMED CORPORATION's annual report to the U.S. Securities and Exchange Commission, filed 17 February 2026. Every sentence was checked against that document before publication.

Growth

USD 1.4B
Revenue, FY2025 · full 17-year series below
Revenue $B Net income $B
FY2025 · Revenue 1.4 · Net income 0.0
0.5B1.0B
2009201220152018202120242025
Compound annual growth
+9.6%
+9.8%
+6.7%
+4.5%
+37.7%
+4.4%
+3.0%
+36.4%
+3.3%
+2.5%
−9.1%
−5.6%
−2.8%
+1.1%
+1.6%
+1.1%
+1.1%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +9.8% a year over the five years to FY2025 — but profit grew faster: net income at +37.7%, earnings per share at +36.4%.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

3 cents
of every revenue dollar became profit
Operating margin Net margin
FY2025 · Operating 7.5% · Net 3.4%
5%10%15%-2%-4%-6%
200920172025
ROE
FY2025 · ROE 4.7%
5%10%-5%-10%
200920172025
Three returns, three denominators.
Gross margin54.6%
Operating margin7.5%
Net margin3.4%
EBITDAUSD 119.8M

Each USD of equity produced 5 cents of profit this year.

Cash & shareholders

USD 24.7M
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF 150.9
100M200M
200920172025
Net buybacks $M Dividends $M
FY2025 · Dividends 24.7 · Net buybacks ·
20M40M-2M-4MDividendsNet buybacks
200920112013201520172019202120232025
Dividends paidUSD 24.7M
Net buybacks·
Share of profit52.6%
Consecutive raises·

USD 24.7M in dividends — 53% of the year's profit went back to shareholders.

Total assetsUSD 2.3B
EquityUSD 1.0B
CashUSD 40.8M
Gross debtUSD 834.2M
Net debtUSD 793.4M
Current ratio2.14×

Net debt stands at 77% of equity.

The 17-year record

17 fiscal years
Every figure from documents filed with the SEC · USD
row low → row highnegative—not applicable◌not available in our data
CNMD, 17-year financial record
Metric 20252024202320222021202020192018201720162015201420132012201120102009
Revenue $B1.41.31.21.01.00.91.00.90.80.80.70.70.80.80.70.70.7
Operating income $B0.10.20.10.10.10.00.10.10.00.00.10.10.10.10.00.10.0
EBITDA $B0.10.20.10.10.10.10.10.10.10.10.10.10.10.10.00.10.0
Income tax $B0.00.00.00.00.0−0.00.00.0−0.00.00.00.00.00.0−0.00.00.0
Net income $B0.00.10.1−0.10.10.00.00.00.10.00.00.00.00.00.00.00.0
Free cash flow $B0.20.20.10.00.10.10.10.10.10.00.00.00.10.10.10.00.0
EPS, diluted $1.514.252.04−2.681.940.320.971.411.970.521.091.161.281.410.031.050.42
Dividend / sh $0.600.800.800.800.800.800.800.800.800.800.800.800.650.600.000.00◌
Payout %531938−30372407955401517268463200—
ROE %4.714.78.2−10.58.41.34.26.39.22.55.25.45.96.90.15.22.1

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

MCK · COR · CAH · JNJ · HCA · LLY
Provenance

Company facts, as filed

How we verify · 0 failures in 83 reconciliationsAUDITED

Reconciled in 17 of the 17 fiscal years we could check. Six checks were skipped: the balance sheet is not tagged before 2010. Two checks were skipped: EPS is not tagged before 2009. Two checks were skipped: revenue is not tagged before 2009.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityElectromedical & Electrotherapeutic Apparatus
Listed onNYSE
Incorporated inDelaware
Fiscal year endsDecember 31
Data on record since2009

Share this section

Download image